NICE recommends Novartis’ Rydapt for advanced SM treatment

The twice-daily, oral drug improves overall survival of people with the rare blood disorder
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Rydapt (midostaurin) for the treatment of aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasms or mast cell leukaemia (three different subtypes of advanced SM).

Read the source article at pmlive.com
2021-08-23 04:17:32